World’s First Halal Biosimilar to Be Produced in Malaysia
Highlights: Malaysia’s VentureTECH, Duopharma Biotech Bhd, and PanGen Biotech from South Korea have joined hands to establish a commercial biosimilar production center in Malaysia. The plant is set to start operations in 2024 and will be the first halal-certified biosimilar production facility in the world. One of the biosimilars that will be produced in the new plant is PanGen’s epoetin alfa biosimilar, which will be sold under the brand names Erisa and Erysaa. Erysaa is an erythropoiesis-stimulating agent that is indicated for the treatment of anemia associated with chronic renal failure in adult hemodialysis and predialysis patients, as well as pediatric patients on hemodialysis. Duopharma Biotech has already commercialized Zuhera, which is a trastuzumab (Herceptin) biosimilar. Trastuzumab is a medication that targets HER2-positive breast cancer and is used to treat both early and metastatic forms of the disease.
Link to Original Article
https://www.centerforbiosimilars.com/view/worlds-first-halal-biosimilar-to-be-produced-in-malaysia